Drug trial marks “profound step forward”
An Alzheimer’s drug being trialled by the Japanese pharmaceutical firm Eisai has shown promising results in slowing down patients’ decline in memory and thinking. The drug, called lecanemab, is currently undergoing a rigorous phase 3 trial and works by removing Alzheimer’s trademark amyloid protein from the brain. Results so far indicate that things like memory,…